American Society of Hirudotherapy

Thrombin inhibition by hirudin: how hirudin inhibits thrombin

Review published in Haemostasis (1991)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentFenton J et al. · Haemostasis, 1991

Abstract

In addition to its classical active-site regions (catalytic site and adjacent regions), alpha-thrombin has a unique anion-binding exosite, which is functionally independent of the catalytic site and is involved in fibrin(ogen) recognition. This exosite also accounts for adhesion to negatively charged surfaces (e.g., glass), binding to cell surfaces, and interactions with the anionic tail of hirudin. Hirudin (as an apolar, tridisulfide-linked core structure followed by its anionic tail) interacts with alpha-thrombin by apolar (e.g., catalytic-site and adjacent regions of thrombin), as well as by ionic binding (e.g., anion-binding exosite). Circular dichroism measurements reveal a sigmoidal nonadditivity for the hirudin tail fragments, which block fibrinogen-clotting activity without interfering with tripeptide chromogenic substrate activities. Such fragments, however, inhibit factor V activation to much lesser extents than hirudin, where factor V activation is the key step in regulating thrombin generation by hirudin or heparin/antithrombin III. Hirudin-derived antithrombotics may thus have differential modes of action in hemostasis and wound healing processes.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.Review
Indexed MeSH termsAmino Acid SequenceAnimalsAnionsBinding SitesCircular DichroismEnzyme ActivationFactor VFibrinogenHirudinsMolecular Sequence DataMolecular StructurePeptide FragmentsProtein BindingProthrombinStructure-Activity RelationshipThrombin

Summary

Structure-function work shows hirudin's apolar core binds thrombin's active-site region while its acidic tail engages the fibrin(ogen)-recognition anion-binding exosite. C-terminal tail fragments block fibrinogen clotting but, unlike intact hirudin, only weakly inhibit factor V activation.

Why This Matters for Hirudotherapy

This study examined the molecular mechanism by which hirudin inhibits alpha-thrombin, characterizing how hirudin's apolar, tridisulfide-linked core and anionic tail engage both thrombin's catalytic site and its functionally independent anion-binding exosite. Circular dichroism experiments revealed that hirudin tail fragments block fibrinogen-clotting activity without affecting tripeptide chromogenic substrate hydrolysis, yet inhibit factor V activation less potently than intact hirudin—a step identified as key in regulating thrombin generation. These findings are mechanistically relevant to understanding hirudin as a direct thrombin inhibitor, since the abstract itself concludes that hirudin-derived antithrombotics may have differential modes of action in hemostasis and wound healing. However, the abstract makes no mention of leeches, salivary secretions, or leech therapy, so the connection to hirudotherapy is indirect, limited to the molecular pharmacology of the thrombin–hirudin interaction rather than any clinical or organism-level context.

Citation

Reference (Vancouver style)

Fenton JW 2nd, Villanueva GB, Ofosu FA, Maraganore JM. Thrombin inhibition by hirudin: how hirudin inhibits thrombin. Haemostasis. 1991;21 Suppl 1:27-31. doi:10.1159/000216259. PMID: 1894193

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: March 18, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.